Pressrelease published on the CymaBay Seladelpar study!
Take the opportunity to read the pressrelease on the CymaBay study with Seladelpar in the NIF mouse. Ed Cable, sr. Director of Research at CymaBay Therapeutics, gives his view on why CymaBay chose to work [...]
Check out CymaBay Therapeutics poster on the NIF mouse at AASLD!
We are very happy that CymaBay Therapeutics chose to present the convincing data from their study in the NIF mouse. They nicely show that Seladelpar, which is a substance in clinical studies, reduces fibrosis in [...]
The NIF mouse in Cyma Bay preclinical study using Seladelpar
We are happy and proud that our NIF mouse is the model used in the preclinical poster presented by Cymabay Therapeutics at the upcoming AASLD meeting, with the title "Seladelpar reduces established liver and renal [...]
Take a look at InfiCures poster from the EASL NAFLD Summit!
InfiCure Bio attended the EASL NAFLD Summit in September, and presented this poster with up-to-date data on the NIF mouse.
Lena Söderström speaks at LXS Nordic Congress 8th of September
Lena Söderström, Head of board at InfiCureBio, will share her views on listing of companies. Take the opportunity to listen to her experiences!
InfiCure Bio will participate with a poster at EASL NAFLD Summit on September 16-17
Inficure Bio will attend the EASLE NAFLD Summit, and present a poster on the NIF mouse. Don't miss the opportunity to take part of the latest updates on how to use the NIF mouse for [...]